TAREG
As listed in the register: TAREG 40 mg, comprimé pelliculé sécable
40 mg · comprimé pelliculé sécable
- Prescription only
- Active substance
- Valsartan
- Made by
- NOVARTIS PHARMA
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (valsartan). It describes the substance, not this Bulgarian product — its uses and doses can differ.
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).
Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.
In vitro metabolism studies involving recombinant CYP 450 enzymes indicated that the CYP 2C9 isoenzyme is responsible for the formation of valeryl-4-hydroxy valsartan.
Effect of Food With the tablet, food decreases the exposure (as measured by AUC) to valsartan by about 40% and peak plasma concentration (C max ) by about 50%.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-06-25
Safety of the active substance
This product’s leaflet is published as a scanned document. This section quotes the US prescribing label for the same active substance (valsartan). It describes the substance, not this Bulgarian product — its uses and doses can differ.
WARNING: FETAL TOXICITY.
- Do not use in patients with known hypersensitivity to any component.
- Do not coadminister aliskiren with valsartan tablets in patients with diabetes [see Drug Interactions ( 7.3 )].
- Known hypersensitivity to any component.
The most common reasons for discontinuation of therapy with valsartan were headache and dizziness.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States28 matching products
Bulgaria3 matching products
Canada8 matching products
Netherlands8 matching products
- Vagrecor 40 mg filmomhulde tabletten 40 mg · filmomhulde tablet
- Valsartan Aurobindo 40 mg filmomhulde tabletten 40 mg · filmomhulde tablet
- Valsartan CF 40 mg 40 mg · filmomhulde tablet
- Valsartan Jubilant 40 mg 40 mg · filmomhulde tablet
- Valsartan Krka 40 mg filmomhulde tabletten 40 mg · filmomhulde tablet
- Valsartan Sandoz 40 mg 40 mg · filmomhulde tablet
- Valsartan Viatris 40 mg 40 mg · filmomhulde tablet
- Valsartan Xiromed 40 mg filmomhulde tabletten 40 mg · filmomhulde tablet
Details
| Made by | NOVARTIS PHARMA |
|---|---|
| Active substance | Valsartan |
| Strength | 40 mg |
| Form | comprimé pelliculé sécable |
| Route | orale |
| Dispensing (as stated by the register) | liste I |
| Marketed | Yes, according to the register |
| Authorisation procedure | Procédure de reconnaissance mutuelle |
| Name in the register | TAREG 40 mg, comprimé pelliculé sécable |
| Packs | plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 30 comprimé(s) ( abrogée le 07/10/2024) · plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 90 comprimé(s) ( abrogée le 07/10/2024) · plaquette(s) PVC PVDC aluminium de 30 comprimé(s) · plaquette(s) PVC PVDC aluminium de 90 comprimé(s) |
| CIS | 67813947 |
| CIP13 | 3400937138062 |
| CIP13 | 3400937138123 |
| CIP13 | 3400938154061 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.